or pharmaceutical acceptable salts thereof wherein:

G is

 R_1 is

- a) H,
- b) NH₂,
- c) NH-C₁₄ alkyl,
- d) C₁₋₄ alkyl,
- e) -OC₁₋₄ alkyl,
- f) -S C₁₋₄ alkyl,
- g) C₁₄ alkyl substituted with 1-3 F, 1-2 Cl, CN or -COOC₁₄ alkyl,
- h) C₃₋₆ cycloalkyl,
- i) N(C₁₄ alkyl)₂ or
- j) $N(CH_2)_{2.5}$;

A is

a 5-membered heteroaromatic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the 5-membered heteroaromatic moiety is bonded via a carbon atom,

wherein the 5-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring,

wherein the heteroaromatic moiety is optionally substituted with one to three R_{48} ,

e) a 6-membered heteroaromatic moiety having at least one nitrogen atom,
wherein the heteroaromatic moiety is bonded via a carbon atom,

wherein the 6-membered heteroaromatic moiety can additionally have a fused-on benzene or naphthyl ring,

wherein the heteroaromatic moiety is optionally substituted with one to three R_{55} ,

f) a β -carbolin-3-yl, or indolizinyl bonded via the 6-membered ring, optionally substituted with one to three R_{55} , ...

wherein R₂ is

- a) H,
- b) F,
- c) Cl,
- d) Br,
- e) C₁₋₃ alkyl,
- f) NO_2 , or
- g) R_2 and R_3 taken together are -O-(CH₂)_h-O-;

R₃ is

- a) $-S(=O)_i R_4$
- b) $-S(=O)_2-N=S(O)_iR_5R_6$,
- c) $-SC(=O)R_{7}$,
- d) $-C(=O)R_8$,
- e) $-C(=O)R_9$,
- f) $-C(=O)NR_{10}R_{11}$,
- g) $-C(=NR_{12})R_8$,
- h) $-C(R_8)(R_{11})-OR_{13}$,
- i) $-C(R_9)(R_{11})-OR_{13}$,
- j) $-C(R_8)(R_{11})-OC(=O)R_{13}$,
- k) $-C(R_9)(R_{11})-OC(=O)R_{13}$,
- 1) $-NR_{10}R_{11}$,
- m) $-N(R_{10})-C(=O)R_7$,
- n) $-N(R_{10})-S(=O)_iR_7$,
- o) $-C(OR_{14})(OR_{15})R_8$,
- p) $-C(R_8)(R_{16})-NR_{10}R_{11}$, or
- q) $C_{1.8}$ alkyl substituted with one or more =0 other than at alpha position, -S(=O)_iR₁₇, -NR₁₀R₁₁, C_{2.5} alkenyl, or C_{2.5} alkynyl;

R4 is

a) C_{14} alkyl optionally substituted with one or more halos, OH, CN, $NR_{10}R_{11}$, or $-CO_2R_{13}$,



- b) C₂₋₄ alkenyl,
- c) $-NR_{16}R_{18}$,
- $d) -N_3,$
- e) $-NHC(=O)R_7$
- f) $-NR_{20}C(=O)R_7$,
- g) $-N(R_{19})_2$,
- h) $-NR_{16}R_{19}$, or
- i) $-NR_{19}R_{20}$,

 $R_{\scriptscriptstyle{5}}$ and $R_{\scriptscriptstyle{6}}$ at each occurrence are the same or different and are

- a) C₁₋₂ alkyl, or
- b) R_5 and R_6 taken together are -(CH₂)_k-;

R₇ is C₁₋₄ alkyl optionally substituted with one or more halos;

R₈ is

- a) H, or
- b) C₁₋₈ alkyl optionally substituted with one or more halos, or C₃₋₈ cycloalkyl;

R, is C14 alkyl substituted with one or more

- a) $-S(=O)R_{17}$
- b) -OR₁₃,
- c) $-OC(=O)R_{13}$,
- d) $-NR_{10}R_{11}$, or
- e) C_{1.5} alkenyl optionally substituted with CHO;

 R_{10} and R_{11} at each occurrence are the same or different and are

- a) H,
- b) C₁₄ alkyl, or
- c) C₃₋₈ cycloalkyl;

 R_{12} is

- a) $-NR_{10}R_{11}$,
- b) $-OR_{10}$; or
- c) -NHC(=0) R_{10} ;



 R_{13} is

- a) H, or
- b) C₁₄ alkyl;

 R_{14} and R_{15} at each occurrence are the same or different and are

- a) C₁₄ alkyl, or
- b) R₁₄ and R₁₅ taken together are -(CH)₁-;

R₁₆ is

- a) H,
- b) C₁₋₄ alkyl, or
- c) C₃₋₈ cycloalkyl;

 R_{17} is

- a) C₁₋₄ alkyl, or
- b) C_{3.8} cycloalkyl;

 R_{18} is

- a) H.
- b) C₁₋₄ alkyl,
- c) C₂₋₄ alkenyl,
- d) C₃₋₄ cycloalkyl,
- e) $-OR_{13}$ or
- f) $-NR_{21}R_{22}$;

 R_{19} is

- a) Cl,
- b) Br, or
- c) I;

R₂₀ is a physiologically acceptable cation;

 R_{21} and R_{22} at each occurrence are the same or different and are

- a) H,
- b) C₁₄ alkyl, or
- c) -NR₂₁R₂₂ taken together are -(CH₂)_m-;

wherein R_{23} and R_{24} at each occurrence are the same or different and are

- a) H,
- b) F,



- c) Cl,
- d) C₁₋₂ alkyl,
- e) CN
- f) OH,
- g) C_{1.2} alkoxy,
- h) nitro, or
- i) amino;

Q is

a)

×

b)



c)



d)



e)

f)





h)



i)

j)



k)

l)

m) a diazinyl group optionally substituted with X and Y,

n) a triazinyl group optionally substituted with X and Y,

o) a quinolinyl group optionally substituted with X and Y,

p) a quinoxalinyl group optionally substituted with X and Y,

q) a naphthyridinyl group optionally substituted with X and Y,

r)

$$A^{1} \xrightarrow{A^{2}} (CH_{2})_{n}$$

$$Z^{1} \xrightarrow{N} N$$

s)

t)

u)

v)

Cont


x)

y)

z)


aa)

bb)



or,

Q and R_{24} taken together are



wherein Z1 is

- -CH₂-, a)
- $-CH(R^{104})-CH_{2}$ -, b)
- -C(O)-, or c)
- d) -CH₂CH₂CH₂-;

wherein Z² is

- -O₂S-, a)
- -O-, b)
- $-N(R^{107})$ -, c)
- -OS-, or d)
- -S-; e)

wherein Z³ is

- -O₂S-, a)
- -O-, b)
- -OS-, or c)
- d) -S-;

wherein A¹ is

- H-, or a)
- CH₃; b)

wherein A² is

- a) H-,
- b) HO-,
- c) CH₃-,
- d) CH_3O_{-}
- e) $R^{102}O-CH_2-C(O)-NH-$
- f) R¹⁰³O-C(O)-NH-,
- g) (C_1-C_2) alkyl-O-C(O)-,
- h) HO-CH₂-,
- i) CH₃O-NH-,
- j) (C₁-C₃)alkyl-O₂C-
- k) $CH_3-C(O)$ -,
- l) CH_3 -C(O)- CH_2 -,

m)



, or

n)



A¹ and A² taken together are:

a)

b)

o=

, or

wherein R102 is

- a) H-,
- b) CH₃-,
- c) phenyl-CH₂-, or
- d) $CH_3C(O)$ -;

wherein R¹⁰³ is

- a) (C₁-C₃)alkyl-, or
- b) phenyl-;

wherein R¹⁰⁴ is

- a) H-, or
- b) HO-;

wherein R¹⁰⁵ is

- a) H-,
- b) (C_1-C_3) alkyl-,
- c) $CH_2 = CH-CH_2$, or
- d) $CH_3-O-(CH_2)_2-;$

wherein R¹⁰⁶ is

- a) CH_3 -C(O)-,
- b) H-C(O)-,
- c) $Cl_2CH-C(O)$ -,
- d) $HOCH_2$ -C(O)-,
- e) CH₃SO₂-,

Cirt

- g) $F_2CHC(O)$ -,
- h) N N-C(O)-
- i) H₃C-C(O)-O-CH₂-C(O)-,
- j) H-C(O)-O-CH₂-C(O)-,
- k) (°)-C(O)-
- l) HC=C-CH₂O-CH₂-C(O)-, or
- m) phenyl-CH₂-O-CH₂-C(O)-;

wherein R107 is

- a) $R^{102}O-C(R^{110})(R^{111})-C(O)-$,
- b) $R^{103}O-C(O)-$,
- c) R^{108} -C(O)-,

- f) H₃C-C(O)-(CH₂)₂-C(O)-,
- g) R^{109} -SO₂-,

h)

i) $HO-CH_2-C(O)-$,

- j) R^{116} - $(CH_2)_2$ -,
- k) R¹¹³-C(O)-O-CH₂-C(O)-,
- l) (CH₃)₂N-CH₂-C(O)-NH-,
- m) $NC-CH_2-$,
- n) F_2 -CH-CH₂-, or
- o) $R^{160}R^{161}NSO_2$

wherein R¹⁰⁸ is

- a) H-,
- b) (C_1-C_4) alkyl,
- c) aryl $-(CH_2)_p$,
- d) ClH₂C-,
- e) Cl₂HC-,
- f) FH₂C-,
- g) F_2HC_- ,
- h) (C₃-C₆)cycloalkyl, or
- i) CNCH₂-.

wherein R^{109} is

- a) $alkylC_1-C_4$,
- b) -CH₂Cl
- c) $-CH_2CH=CH_2$,
- d) aryl, or
- e) -CH₂CN;

wherein R110 and R111 are independently

- a) H-,
- b) CH_3 -; or

wherein R¹¹² is

- a) H-,
- b) CH₃O-CH₂O-CH₂-, or
- c) HOCH₂-;



wherein R113 is

- a) CH₃-,
- HOCH,-, b)
- (CH₃)₂N-phenyl, or c)
- (CH₃)₂N-CH₂-; d)

wherein R114 is

- a) HO-,
- CH₃O-, b)
- H₂N-, c)
- CH,O-C(O)-O-. d)
- CH_3 -C(O)-O- CH_2 -C(O)-O-, e)
- phenyl-CH₂-O-CH₂-C(O)-O-, f)
- HO-(CH₂)₂-O-, g)
- $CH_3O-CH_2-O-(CH_2)_2-O-$, or h)
- CH₃O-CH₂-O-; wherein R¹¹³ is i)
- CH₃-, a)
- HOCH₂-, b)
- $(CH_3)_2N$ -phenyl, or c)
- $(CH_3)_2N-CH_2-;$ d)

wherein R115 is

- H-, or a)
- Cl-; b)

wherein R¹¹⁶ is

- HOa)
- CH₃O-, or b)
- c)

wherein R^{150} and R^{151} are each H or alkyl C_i - C_4 or R^{150} and R^{151} taken together with the nitrogen atom to which each is attached form a monocyclic heterocyclic ring having from 3 to 6 carbon atoms;

B is an unsaturated 4-atom linker having one nitrogen and three carbons; M is



- a) H,
- b) C₁₋₈ alkyl,
- c) C₃₋₈ cycloalkyl,
- d) $-(CH_2)_mOR_{13}$, or
- e) $-(CH_2)_b-NR_{21}R_{22}$;

Z is

- a) O,
- b) S, or
- c) NM;

W is

- a) CH,
- b) N, or
- c) S or O when Z is NM;

Y is

- a) H,
- b) F,
- c) Cl,
- d) Br,
- e) C₁₋₃ alkyl, or
- f) NO_2 ;

X is

- a) H,
- b) -CN,
- c) OR₂₇,
- d) halo,
- e) NO₂,
- f) tetrazoyl,
- g) -SH,
- h) $-S(=O)_iR_4$,
- i) $-S(=O)_2-N=S(O)_jR_5R_6$,

Chy)

- j) -SC(=O) R_7 ,
- $k) -C(=O)R_{25},$
- 1) $-C(=O)NR_{27}R_{28}$,
- m) $-C(=NR_{29})R_{25}$,
- n) $-C(R_{25})(R_{28})-OR_{13}$,
- o) $-C(R_{25})(R_{28})-OC(=O)R_{13}$,
- p) $-C(R_{28})(OR_{13})-(CH_2)_h-NR_{27}R_{28}$,
- q) $-NR_{27}R_{28}$,
- r) $-N(R_{27})C(=O)R_{7}$,
- s) $-N(R_{27})-S(=O)_iR_7$,
- t) $-C(OR_{14})(OR_{15})R_{28}$,
- u) $-C(R_{25})(R_{16})-NR_{27}R_{26}$, or
- v) $C_{1.8}$ alkyl substituted with one or more halos, OH, =O other than at alpha position, -S(=O)_iR₁₇, -NR₂₇R₂₈, C_{2.5} alkenyl, C_{2.5} alkynyl, or $C_{3.8}$ cycloalkyl;

 $R_4,\,R_5,\,R_6,\,R_7,\,R_{13},\,R_{14},\,R_{15},\,R_{16},$ and R_{17} are the same as defined above; R_{25} is

- a) H,
- b) $C_{1.8}$ alkyl optionally substituted with one or more halos, $C_{3.8}$ cycloalkyl, $C_{1.4}$ alkyl substituted with one or more of -S(=O)_iR₁₇, -OR₁₈, or OC(=O)R₁₈, NR₂₇R₂₈, or
- c) C_{2.5} alkenyl optionally substituted with CHO, or CO₂R₁₃;

R₂₆ is

- a) R_{28} , or
- b) $NR_{27}N_{28}$;

 $R_{\mbox{\tiny 27}}$ and $R_{\mbox{\tiny 28}}$ at each occurrence are the same or different and are

- a) H,
- b) C₁₋₈ alkyl,
- c) C₃₋₈ cycloalkyl,
- d) $-(CH_2)_mOR_{13}$,



- e) $-(CH_2)_h-NR_{21}R_{22}$, or
- f) R_{27} and R_{28} taken together are -(CH₂)₂O(CH₂)₂-, -(CH₂)_bCH(COR₇)-, or -(CH₂)₂N(CH₂)₂(R₇);

R₂₉ is

- a) $-NR_{27}R_{28}$,
- b) -OR₂₇, or
- c) $-NHC(=O)R_{28}$;

wherein R_{30} is

- a) H,
- b) C_{1.8} alkyl optionally substituted with one or more halos, or
- c) C_{1-8} alkyl optionally substituted with one or more OH, or C_{1-6} alkoxy;

wherein E is

- a) NR₃₉,
- b) $-S(=O)_i$, or
- c) O;

R_{38} is

- a) H,
- b) C₁₋₆ alkyl,
- c) $-(CH_2)_q$ -aryl, or
- d) halo;

R_{39} is

- a) H,
- b) C₁₆ alkyl optionally substituted with one or more OH, halo, or -CN,
- c) $-(CH_2)_q$ -aryl,
- d) $-CO_2R_{40}$,
- e) -COR₄₁,
- f) $-C(=O)-(CH_2)_q-C(=O)R_{40}$,
- g) $-S(=O)_2-C_{1-6}$ alkyl,
- h) $-S(=O)_2-(CH_2)_q$ -aryl, or
- i) $-(C=O)_i$ -Het;



R₄₀ is

- a) H,
- b) C₁₋₆ alkyl optionally substituted with one or more OH, halo, or -CN,
- c) $-(CH_2)_q$ -aryl, or
- d) $-(CH_2)_q-OR_{42};$

R41 is

- a) C₁₋₆ alkyl optionally substituted with one or more OH, halo, or -CN,
- b) -(CH₂)₀-aryl, or
- c) -(CH₂)_q-OR₄₂;

 R_{42} is

- a) H,
- b) C₁₋₆ alkyl,
- c) $-(CH_2)_q$ -aryl, or
- d) $-C(=O)-C_{1-6}$ alkyl;

aryl is

- a) phenyl,
- b) pyridyl, or
- c) napthyl; a to c optionally substituted with one or more halo, -CN, OH, SH, C_{1.6} alkyl, C_{1.6} alkoxy, or C_{1.6} alkylthio;

wherein R43 is

- a) H,
- b) C₁₋₂ alkyl,
- c) F, or
- d) OH;

R44 is

- a) H,
- b) CF₃,
- c) C₁₃ alkyl optionally substituted with one or more halo,
- d) phenyl optionally substituted with one or more halo,

C'y

e) R₄₄ and R₄₅ taken together are a 5-, 6-, or 7-membered ring of the formula,

or

f) R_{44} and R_{45} taken together are -(CH₂)_k-, when R_{46} is an electron-withdrawing group;

 $R_{45} \; and \; R_{46} \; at \; each \; occurrence \; are \; the same or different and are$

- a) an electron-withdrawing group,
- b) H,
- c) CF₃,
- d) C₁₃ alkyl optionally substituted with one halo,
- e) phenyl, provided at least one of R_{45} or R_{46} is an electron-withdrawing group, or
- f) R₄₅ and R₄₆ taken together are a 5-, 6-, 7-membered ring of the formula

U is

- a) CH_2 ,
- b) O,
- c) S, or
- d) NR₄₇;



R₄₇ is

- a) H, or
- b) C₁₋₅ alkyl;

wherein R48 is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF_3 ,
- g) $-NO_2$,
- h) C_{1.6} alkoxy,
- i) C₁₋₆ alkoxycarbonyl,
- j) C₁₋₆ alkythio,
- k) C_{1-6} acyl,
- 1) $-NR_{49}R_{50}$,
- m) $C_{1.6}$ alkyl optionally substituted with OH, $C_{1.5}$ alkoxy, $C_{1.5}$ acyl, or $-NR_{49}R_{50}$,
- n) $C_{2.8}$ alkenylphenyl optionally substituted with one or two R_{51} ,
- o) phenyl optionally substituted with one or two R_{51} ,
- p) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R_{51} , or

 $R_{49} \ \text{and} \ R_{50}$ at each occurrence are the same or different and are

- a) H,
- b) C₁₄ alkyl,
- c) C₅₋₆ cycloalkyl, or



d) R₄₉ and R₅₀ taken together with the nitrogen atom is a 5-, 6membered saturated heterocyclic moiety which optionally has a
further hetero atom selected from the group consisting of S, N, and O,
and can in turn be optionally substituted with, including on the
further nitrogen atom, C₁₋₃ alkyl, or C₁₋₃ acyl;

R_{61} is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF_3 ,
- g) -NO₂,
- h) C₁₋₆ alkoxy,
- i) C_{1.6} alkoxycarbonyl,
- j) C₁₋₆ alkythio,
- k) C_{1-6} acyl,
- l) C_{1-6} alkyl optionally substituted with OH, C_{1-6} alkoxy, C_{1-6} acyl, or -NR₄₉R₅₀,
- m) phenyl,
- n) $-C(=O)NR_{52}R_{53}$,
- o) $-NR_{49}R_{50}$,
- p) $-N(R_{52})(-SO_2R_{54})$,
- q) $-SO_2-NR_{52}R_{53}$, or
- r) $-S(=O)_{i}R_{54};$

R₅₂ and R₅₃ at each occurrence are the same or different and are

- a) H,
- b) C₁₋₆ alkyl, or
- c) phenyl;



R₅₄ is

- a) C₁₄ alkyl, or
- b) phenyl optionally substituted with C₁₄ alkyl;

wherein R₅₅ is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF_3 ,
- g) -NO₂,
- h) C₁₋₆ alkoxy,
- i) C₁₋₆ alkoxycarbonyl,
- j) C₁₋₆ alkythio
- k) C₁₋₆ acyl,
- 1) $-NR_{56}R_{57}$,
- m) $C_{1.5}$ alkyl optionally substituted with OH, $C_{1.5}$ alkoxy, $C_{1.5}$ acyl, or -NR₅₆R₅₇,
- n) $C_{2.8}$ alkenylphenyl optionally substituted with one or two R_{58} ,
- o) phenyl optionally substituted with one or two R₅₈,
- p) a 5- or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with one or two R_{58} , or

(CH₂)₁

 R_{56} and R_{57} at each occurrence are the same or different and are

- a) H,
- b) formyl,

Chi

- c) C₁₄ alkyl,
- d) C_{14} acyl,
- e) phenyl,
- f) C_{3.6} cycloalkyl, or
- R₅₆ and R₅₇ taken together with the nitrogen atom is a 5-, 6-membered saturated heterocyclic moiety which optionally has a further hetero atom selected from the group consisting of S, N, and O, and can in turn be optionally substituted with, including on the further nitrogen atom, phenyl, pyrimidyl, C₁₋₃ alkyl, or C₁₋₃ acyl;

R₅₈ is

- a) carboxyl,
- b) halo,
- c) -CN,
- d) mercapto,
- e) formyl,
- f) CF₃,
- g) -NO₂,
- h) C₁₋₆ alkoxy,
- i) C_{1.6} alkoxycarbonyl,
- j) C₁₋₆ alkythio,
- k) C_{1.6} acyl,
- l) phenyl,
- m) $C_{1.6}$ alkyl optionally substituted with OH, azido, $C_{1.5}$ alkoxy, $C_{1.5}$ acyl, -NR₆₅R₆₆, -SR₆₇, -O-SO₂R₆₈, or

- n) $-C(=O)NR_{69}R_{60}$,
- o) $-NR_{56}R_{57}$,
- p) $-N(R_{59})(-SO_2R_{54}),$

- q) $-SO_2-NR_{59}R_{60}$,
- r) $-S(=O)_{i}R_{54}$,
- $_{6}$) -CH=N-R₆₁, or
- t) $-CH(OH)-SO_3R_{64}$;

R₅₄ is the same as defined above;

 $R_{\rm 59}$ and $R_{\rm 60}$ at each occurrence are the same or different and are

- a) H,
- b) C₁₋₆ alkyl,
- c) phenyl, or
- d) tolyl;

R₆₁ is

- a) OH,
- b) benzyloxy,
- c) $-NH-C(=O)-NH_2$,
- d) $-NH-C(=S)-NH_2$, or
- e) -NH-C(=NH)-N $R_{62}R_{63}$;

 R_{62} and R_{63} at each occurrence are the same or different and are

- a) H, or
- b) C₁₄ alkyl optionally substituted with phenyl or pyridyl;

 R_{64} is

- a) H, or
- b) a sodium ion;

 R_{65} and R_{66} at each occurrence are the same or different and are

- a) H,
- b) formyl,
- c) C₁₋₄ alkyl,
- d) C₁₋₄ acyl,
- e) phenyl,
- f) C₃₋₆ cycloalkyl,



- g) R₅₅ and R₆₆ taken together are a 5-, 6-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with, including on the nitrogen atom, phenyl, pyrimidyl, C₁₋₃ alkyl, or C₁₋₃ acyl,
- h) $-P(O)(OR_{70})(OR_{71})$, or
- i) $-SO_2-R_{72}$;

 R_{67} is

CH3

CH3

R₆₈ is C₁₋₃ alkyl;

R₆₉ is

- a) C_{1.6} alkoxycarbonyl, or
- b) carboxyl;

 R_{70} and R_{71} at each occurrence are the same or different and are

- a) H, or
- b) C_{1.3} alkyl;

R_{72} is

- a) methyl,
- b) phenyl, or
- c) tolyl;

wherein K is

- a) O, or
- b) S;

 R_{73} , R_{74} , R_{75} , R_{76} , and R_{77} at each occurrence are the same or different and are

- a) H,
- b) carboxyl,
- c) halo,
- d) -CN,
- e) mercapto,
- f) formyl,
- g) CF₃,
- h) -NO₂,
- i) C₁₋₆ alkoxy,
- j) C_{1.6} alkoxycarbonyl,
- k) C_{1.6} alkythio,
- C_{1-6} acyl,
- m) $-NR_{78}R_{79}$,
- n) C₁₋₆ alkyl optionally substituted with OH, C₁₋₅ alkoxy, C₁₋₅ acyl,
 -NR₇₈R₇₉, -N(phenyl)(CH₂-CH₂-OH), -O-CH(CH₃)(OCH₂CH₃), or
 -O-phenyl-[para-NHC(=O)CH₃],
- o) $C_{2.8}$ alkenylphenyl optionally substituted with R_{51} ,
- p) phenyl optionally substituted with R₅₁, or
- q) a 5-, or 6-membered (un)saturated heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, optionally substituted with R₅₁;

R₅₁ is the same as defined above;



 R_{78} and R_{79} at each occurrence are the same or different and are

- a) H,
- b) C₁₄ alkyl,
- c) phenyl, or
- d) R₇₈ and R₇₉ taken together with the nitrogen atom is a 5-, 6membered saturated heterocyclic moiety which optionally has a
 further hetero atom selected from the group consisting of S, N, and O,
 and can in turn be optionally substituted with, including on the
 further nitrogen atom, C₁₋₃ alkyl, or C₁₋₃ acyl;

wherein T is

- a) O,
- b) S, or
- c) SO₂;

 R_{75} , R_{76} , and R_{77} are the same as defined above;

R_{so} is

- a) H,
- b) formyl,
- c) carboxyl,
- d) C_{1.6} alkoxycarbonyl,
- e) C₁₋₈ alkyl,
- f) $C_{2.8}$ alkenyl, wherein the substituents (e) and (f) can be optionally substituted with OH, halo, $C_{1.6}$ alkoxy, $C_{1.6}$ acyl, $C_{1.6}$ alkylthio or $C_{1.6}$ alkoxycarbonyl, or phenyl optionally substituted with halo,
- an aromatic moiety having 6 to 10 carbon atoms optionally substituted with carboxyl, halo, -CN, formyl, CF₃, -NO₂, C_{1.6} alkyl, C_{1.6} alkoxy, C_{1.6} acyl, C_{1.6} alkylthio, or C_{1.6} alkoxycarbonyl;
- h) $-NR_{81}R_{82}$,
- i) $-OR_{90}$,
- j) $-S(=O)_i-R_{91}$
- k) $-SO_2-N(R_{92})(R_{93})$, or
- l) a radical of the following formulas:



 $R_{\rm 81}$ and $R_{\rm 82}$ at each occurrence are the same or different and are

- a) H,
- b) C₃₋₆ cycloalkyl,
- c) phenyl,
- d) C₁₋₆ acyl,
- e) C_{1.8} alkyl optionally substituted with OH, C_{1.6} alkoxy which can be substituted with OH, a 5-, or 6-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, phenyl optionally substituted with OH, CF₃, halo, -NO₂, C_{1.4} alkoxy, -NR₈₃R₈₄, or



$$^{g)}$$
 $\sqrt{N-(CH_2)_t}-$

V is

- a) O,
- b) CH₂, or
- c) NR₈₇;

 R_{83} and R_{84} at each occurrence are the same or different and are

- a) H, or
- b) C₁₄ alkyl;

 R_{85} is

- a) OH,
- b) C₁₋₄ alkoxy, or
- c) $-NR_{88}R_{89}$;

 R_{86} is

- a) H, or
- b) C_{1.7} alkyl optionally substituted with indolyl, OH, mercaptyl, imidazoly, methylthio, amino, phenyl optionally substituted with OH, -C(=O)-NH₂, -CO₂H, or -C(=NH)-NH₂;

R₈₇ is

- a) H,
- b) phenyl, or
- c) C_{1.6} alkyl optionally substituted by OH;

 R_{88} and R_{89} at each occurrence are the same or different and are

- a) H,
- b) C_{1.5} alkyl
- c) C₃₋₆ cycloalky, or
- d) phenyl;

 R_{90} is

a) C_{1.8} alkyl optionally substituted with C_{1.6} alkoxy or C_{1.6} hydroxy, C_{3.6} cycloalkyl, a 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three nitrogen atoms, which can in turn be substituted with one or two -NO₂, CF₃, halo, -CN, OH, C_{1.5} alkyl, C_{1.5} alkoxy, or C_{1.5} acyl;

- c) phenyl, or
- d) pyridyl;

Canx

R₂₁ is

- a) C_{1.16} alkyl,
- b) C₂₋₁₆ alkenyl,
 wherein the substituents (a) and (b) can be optionally substituted with
 C₁₋₆ alkoxycarbonyl, or a 5-, 6-, 7-membered aromatic heterocyclic
 moiety having one to three atoms selected from the group consisting of
 S, N, and O,
- c) an aromatic moiety having 6 to 10 carbon atoms, or
- a 5-, 6-, 7-membered aromatic heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (c) and (d) can be optionally substituted with carboxyl, halo, -CN, formyl, CF₃, -NO₂, C₁₆ alkyl, C₁₆ alkoxy, C₁₆ acyl, C₁₆ alkylthio, or C₁₆ alkoxycarbonyl;

 R_{92} and R_{93} at each occurrence are the same or different and are

- a) H,
- b) phenyl,
- c) C₁₋₆ alkyl, or
- d) benzyl;

 R_{94} and R_{95} at each occurrence are the same or different and are

- a) H,
- b) OH,
- c) C₁₆ alkyl optionally substituted with -NR₈₃ R₈₄, or
- d) R_{94} and R_{95} taken together are =0;

R₉₆ is

- a) an aromatic moiety having 6 to 10 carbon atoms,
- b) a 5-, or 6-membered aromatic optionally benzo-fused heterocyclic moiety having one to three atoms selected from the group consisting of S, N, and O, wherein the substituents (a) and (b) which can in turn be substituted with one or three -NO₂, CF₃, halo, -CN, OH, phenyl, C_{1.5} alkyl, C_{1.5} alkoxy, or C_{1.5} acyl,



- c) morpholinyl,
- d) OH,
- e) C₁₋₆ alkoxy,
- f) $-NR_{83}R_{84}$,
- g) -C(=O)-R₉₇, or
- h) 0

R₉₇ is

- a) morpholinyl,
- b) OH, or
- c) C₁₋₆ alkoxy;

h is 1, 2, or 3;

i is 0, 1, or 2;

j is 0 or 1;

k is 3, 4, or 5;

1 is 2 or 3;

m is 4 or 5;

n is 0, 1, 2, 3, 4, or 5;

p is 0, 1, 2, 3, 4, or 5; with the proviso that n and p together are 1, 2, 3, 4, or 5;

q is 1, 2, 3, or 4;

r is 2, 3, or 4;

t is 0, 1, 2, 3, 4, 5, or 6;

u is 1 or 2;

w is 0, 1, 2, or 3.

Chip

 C^2

7. (amended) A method of treating or preventing osteoporosis, bone resorption, or other bone disease characterized by the need to enhance bone formation in a vertebrate mammal in need thereof comprising the administering to the vertebrate mammal an effective amount of a compound of formula II

$$Z_{2} \stackrel{N}{\underset{(CH_{2})_{w}}{\bigvee}} \stackrel{R^{23}}{\underset{R^{24}}{\bigvee}} \stackrel{O}{\underset{NHC-R^{1}}{\bigvee}} \qquad \text{(II)}$$

wherein Z_2 is $-O_2S_-$, $-O_-$, $-N(R^{107})_-$, $-OS_-$, or $-S_-$;

w is 0, 1, 2, or 3;

R²³ and R²⁴ are the same or different and can be H or F; and

 R^1 is H, NH₂, NHalkyl C_1 - C_4 ; N(alkyl C_1 - C_4)₂;

-NCHzizs ;

alkylC₁-C₄; OalkylC₁-C₄; SalkylC₁-C₄; alkylC₁-C₄ substituted with 1-3F, 1-2Cl, CN, or -COOalkylC₁-C₄, or cycloalkylC₃-C₆, wherein in each occurrence of the alkyl group may be straight or branched; and

R¹⁰⁷ is

- a) $R^{102}O-C(R^{110})(R^{111})-C(O)-$
- b) $R^{103}O-\phi(O)-$
- c) R^{108} -C(O)-,
- d) R^{109} -\$O₂-,
- e) NC-CH₂-,
- f) FCHCH₂-, or
- g) $R^{150}R^{151}NSO_{2}$;

Crital Cortal May

wherein R¹⁰² is H, CH₃-, phenyl-CH₂-, or CH₃C(O); each of R¹¹⁰ and R¹¹¹ is selected from H or CH₃; R¹⁰³ is alkylC₁-C₃ or phenyl; R¹⁰⁸ is H, alkylC₁-C₄, aryl(CH₂)₀₋₅, CNCH₂-, ClCH₂-, Cl₂HC-, FH₂C-, F₂HC-, or cycloalkylC₃-C₆; R¹⁵⁰ and R¹⁵¹ are the same or different and are selected from H, alkylC₁-C₄, or R¹⁵⁰ and R¹⁵¹ taken together with the nitrogen to which each is attached forms a monocyclic heterocyclic ring having from 3 to 6 carbon atoms.